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Background: Advances in the understanding of mitral valve pathology have laid to mitral valve plasty (MPL) as the
procedure of choice of all the mitral intervention as compared to mitral valve replacement (MVR).
This study is aimed to compare the outcome mortality and reoperation and to estimate failure of repair between
the two procedures during the follow up time.
Material and methods: A cohort of 355 patients with mitral valve disease operated between January 1993 to
January 2007 with closing date first of mars 2011. There were 214 MPL and 141 MVR at the Hospital discharge. This
retrospective cohort had the design of exposed (MPL) versus non-exposed (MVR) with outcome total mortality and
reoperation during follow up. Also echocardiography follow-up was undertaken to estimate the true long-term
failure rate of repair.
Results: The mean follow up was 5.3 years SE (3.82) maximum follow up was 14.1 years. Considering the patient time
model the association between repair/replacement and total mortality RR = 0.43 95% (0.28-074) p = 0.002 controlling
for the confounding effect of 3-vessels disease. Those results were confirmed by propensity score analysis.
As far as outcome re-operation, presence of atrial fibrillation AF was an effect modifier indicating lower
reoperation rate for MPL compared to MVR for patients without AF, RR = 0.32 95% CL (0.13-0.81) p = 0.017 while no
difference in reoperation rates between MPL/MVR for patients with AF RR = 1.82 95% CL (0.52-6.4) p = 0.344.
Echocardiography follows up showed incidence of moderate and severe recurrent mitral regurgitation was 1.34
per 100 patients years and 0.27 per 100 patients years during the follow-up time.
Conclusion: In a cohort of patient with mitral valve disease undergoing MPL/MVR was examined. MPL was
associated with better survival, and lower reoperation rate for patients without AF but same rate for patients with
AF. We advocate more attention in controlling risk factors of AF in the clinical management of mitral disease.
Long-term failure rate of MPL was low during follow up time. A replication of our results by a randomized clinical
trial is mandatory.
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Advances in the understanding of mitral valve patho-
physiology and technology has brought mitral valve
plasty (MPL) as the procedure of choice.
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reproduction in any medium, provided the oris not clear that MPL is superior to MVR in all clin-
ical circumstances. So far, no randomised clinical trial
comparing mortality and morbidity after MPL versus
MVR has been undertaken. Hence, our information is
based on the majority of observational studies showing
some evidence for better survival from MPL as compared
to MVR [1,2] The risk of thromboembolism was lower in
MPL without increasing frequency of re operation for
MPL as compared to MVR. Better survival of MPL as
compared to MVR has been observed for patients with
specific aetiologies (rheumatic, mixed or degenerative). In
patients with chronic ischemic regurgitation, there is nol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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one. Recently Murphy et al. [3] suggested performing a
randomised trial to answer this important issue.
Further, sufficient data are not available on failure of MPL
defined by recurrence of moderate or severe mitral regurgi-
tation or reoperation for mitral regurgitation. Postoperative
incidence of recurrent mitral regurgitation is principally an
end-point to evaluate for the long-term outcomes of MPL.
In the absence of echocardiographic follow up, there is no
way of quantifying the long-term failure rate of repair.
This study was aimed to compare the outcome total
mortality and re operation between the two methods
during a long-term follow-up (mean follow up time of
5.3 years). Further, we wanted to highlight the durability
of MPL by a serial of echocardiography done at discharge,
after medium and long term follow up to estimate the rate
in100 patients.year of new recurrent mitral regurgitation.
Methods
A cohort of 355 consecutive patients with mitral valve
disease were operated between January 1993 to December
2007 at Ullevaal University Hospital with a longitudinal
follow up until the closing date of first of March 2007.
There were 214 MPL and 141 MVR at baseline as
primary operation. Twenty procedures were converted
intraoperatively from MPL to MVR and were reported
as MVR at discharge from hospital. Hence, 214 patients
were operated with MPL and 141 with MVR It is important
to emphasize that the whole material of 355 mitral
operations represent all mitral surgical procedures
undertaken at this institution in this period. The study had
been ethically approved by the Head of the Office of Privacy
and Information Security at Oslo University Hospital which
is the juridical responsible organism.
Echocardiography and clinical data
Echocardiography by an experienced cardiologist was
performed pre discharge and after 3,12, 36,60,120 months.
Measurement of mitral regurgitation was performed
according to the American Society of Echocardiography
[4]. Follow up data were collected from the outpatient
department at the local hospitals and their general
practitioners. If no reply was received, the patients were
contacted by telephone. Mortality data were retrieved
from Statistics Norway (www.ssb.no/english/) Autopsy
was mostly but not always performed on patients who
died in hospital. No patient was lost to follow up.
The follow up time in days ranged from 1 to 5160 days
with a mean observation time of 5.3 years SD (3.82), and
the total follow up time represented 1859 patients years.
Surgical considerations
This surgical material consists of all mitral surgical
procedures undertaken at this institution in this period(1993–2007). The same 2 surgeons undertook all opera-
tions. All operations were undertaken with extracorporeal
circulation in moderate hypothermia (32 c c). Myocardial
protection was achieved by antegrad blood cardioplegia.
The MVRs aimed to preserve chordal preservations to the
largest extent possible. Patients older than 70 years received
biological prosthesis (Medtronic Mosaic) and (<70 Years)
received St Jude bileaflet mechanical prosthesis.
In the beginning of this observational period, MVR were
more frequent procedure than MPL. However, after 1998,
about 2/3 of mitral surgical procedures where MPLs.
Different repair procedures were performed in the group
of mitral repair MPL. Mitral ring placed (annuloplasty)
was done usually combined with other procedures in
187 patients.
145 patients got a posterior leaflet resection, 26 patients
got anterior leaflet resection, 16 patients got chordal
shortening, 7 patients had artificial chordea, 7 patients
got chordal transfer and finally 16 patients got other
mitral plasty.
Before hand power estimate
Our before hand power analysis was done considering our
past experience in our centre and information published in
the literature. Our centre results [5] as far as 5 years
survival of the MVR procedure totally was 78% SE (3.0%)
(Cum hazard 22%) and MVR with presence of mitral regur-
gitation 75.5% SE (4.7%) (Cum hazard 24.5%). On the other
hand Cohn LW et al. [6] indicated at 2.5 years of follow up
6% cumulative incidence of mortality for MPL and 15%
cumulative incidence for MVR. This gave an RR = 0.40
pinpointing a 60% reduction of mortality for repair as
compared with replacement. Another investigator Moss RR
et al. [7] considering propensity score matched cohort, indi-
cated at 5 years of follow up a cumulative incidence of mor-
tality of 8% for MPL and 17% for MVR showing an RR =
0.47; i.e. a 53% reduction of mortality in favour of repair.
Considering the mean of the two estimated RR =
(0.41 +0.47)/2 = 0.44 (56% reduction of mortality in
favour of repair) and a cumulative incidence of mortality
at 5 years of 24.5% for MVR [5] an a type I error of 5%
and power of 80% and a ratio of MPL/MVR = 2 we will
need around 212 MPL patients and 106 MVR patients a
total of 318 patients considering 10% dropout.
Gillinov Am et al. [8] pinpointed no difference in the
freedom of re operation survival between repair and
replacement at 5 years (94% versus 95%) p = 0.60. No
power estimated was done as far this end point as there
is no difference in re operation rate between repair and
replacement [1].
Epidemiological design and statistical methods
An observational cohort study design of exposed MPL
versus unexposed MVR was considered with outcome
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major endpoints of the study.
To highlight the major confounders and effect modifier
of the association MPL versus MVR on the effect parame-
ters mortality and re operation we used the Mantel Hanszel
methods. Survival curves using the Kaplan Meier methods
were used with end point total mortality and incidence of
re operation. The log rank test was used to compare
the survival. The Cox’s multivariate model to control
for confounders and interactions [9,10].
Finally, we also considered the propensity score (PS).
We know that non-randomised comparison gives rise to
selection bias. PS is the conditional probability to have
a MPL given the individual covariates [11]. Adjusting
observed MPL with the probability of MVR (propensity)
creates a quasi-randomised experiment. This can be used
to adjust for selection bias via design matching or during
analysis of treatment effect by stratification on quintiles
of the PS in the final Cox’s regression model [12]. The
propensity score was based on 6 variables differently
distributed between the two treatments as age, gender,
ischemic aetiology, atrial fibrillation, ejection fraction,
and degenerative aetiology. Our model is in agreement
with the limitations by Peduzzi et al. [13] pinpointing
the need to have not less than 10 events per covariates.
A review of application of propensity score methods [14]
has showed that there is little evidence that these methods
yield substantially different estimates compared with
conventional multivariable method.
As we are in a prognostic strategy in the propensity
score estimation analysis, the predictive accuracy of the
model was evaluated by calibration and discrimination.
Calibration was evaluated by the Hosmer and Lemeshow
(H-L) goodness of fit test. Discrimination was evaluated
by the analysis of the area under the ROC curve. If the area
under the curve is greater than 0.7, it can be concluded
that the model has an acceptable discriminatory capability
[15]. We assessed the balance in baseline variables between
MPL and MVR patients within quintiles of the Propensity
Score using the standardized difference method (16,17).
The reporting and analysis of our study followed the
suggestions for improvement of [16-18] when combining
classical methods and Propensity score to remove 90%
of measured selection bias due to baseline difference
using quintiles stratification [11]. Unlike randomization,
PS techniques cannot control for unknown or unmeasured
potential confounding factors.
Results
Generating the propensity score
We generated a propensity score by using the logistic model
and including 6 variables as ischemic aetiology, degenerative
aetiology, EF preoperatively, age at operation, gender,
presence of AF preoperatively. The Hosmer-Lemeshow(H-L) test for the model was not significant indicating
a useful goodness of fit for the model. The predictors
of MPL by constructed logistic model demonstrate a
good discriminatory power. Area under the ROC curve
(AUC) was 0.819 95% CL (0.775-0.857).
The assessment of distribution of the baseline variables
between the two procedures MPL and MVR within
quintiles of the PS was satisfactory using the standardized
difference method.
End point mortality
The follow up time inn days ranged from 1 to 5160 days
with a mean observation time of 5.3 years SD (3.82) total
follow up time represented 1859 patients years.
Patients with MPL as compared to MVR were older,
higher frequency of male, less frequency of AF, higher
frequency of MR, less frequent endocarditic aetiology,
lower frequency of significant CHD, higher ejection fraction
and higher frequency of degenerative aetiology (Table 1).
The 5 years survival for MPL group was 90.6% SE
(2.32) and for MVR 75.8% SE (4.28) with log rank test
p = 0.001 (Figure 1). Considering the patients years model
the association between procedures MPL/MVR and total
mortality, was estimated by a Rate Ratio (RR) = 0.48 95%
(0.28-0.80) p = 0.001 indicating a relative reduction of
mortality of MPL versus MVR of 52%. A stratification
analysis using the Mantel-Hanszel methods showed that
the strongest confounder was presence of three vessels
disease with a confounding effect of 6.2% and no effect
modifier. No significant difference in stroke and cerebro
vascular bleeding was found between the MPL group and
the MVR group but a tendency towards lower risk for
MPL as compared to MVR. In this situation we cannot be
conclusive as we are in a situation of power deficiency
Table 2.
Adjusted effect of procedure on total mortality
Controlling for the confounding effect of presence of three
vessels diseases we got an adjusted effect of RR = 0.43
95% CL (0.28-0.74) p = 0.002 taking in consideration
validity and precision, this indicates a relative reduction
of mortality of 57% for MPL as compared to MVR as far
as total mortality Table 3.
Another approach was done by running the stratified
Cox’s model based on quintiles of PS (propensity score)
and controlling for the variable presence of 3 vessels
disease. This analysis gave an RR = 0.54 with 95% CL
(0.32-0.90) p = 0.02 indicating a reduction of mortality
of 46% MPL as compared to MVR at a mean follow up
time of 5.3 years.
Endpoint re operation
At 5 years of follow up patient with MPL had a cumulative
survival free from reoperation of 93.4% SE (1.8%) compared
Table 1 Clinical profile of patient with mitral plasty and
mitral valve replacement
Variables MPL(n = 214) MVR(n = 141)
Age yrs 64(54–72) 62(51–69)*
EF in % 60(50–73) 50(50–63)*
Female 59 59
Presence of Dyspnea 201 133
Presence of angina 43 28
Presence of MR 203 127
Mild Grad-I 3 1
Moderate Grad-II 15 27
Severe Grad-III 181 99
Presence of MR +MS 11 14
Presence of AF 54 55
Presence of AR 25 40
Presence of AS 14 26
Presence of TR 30 31
Presence of PR 2 2
3 vessels disease 32 19




Ischemic MR 29 21
Endocarditis 21 26
Degenerative 120 13
Unknown etiology 46 34
Papillary muscle rupture 10 7
Valve thrombosis 0 1
Previous valve surgery
Previous MVR 2 10
Previous AVR 3 5
Previous plasty 1 3
MS Mitral Stenosis, AF Atrial Fibrillation, AS Aortic Stenosis, TR,
Tricuspid regurgitation.
PR Pulmonary valve regurgitation, AR Aortic regurgitation, (*) Median and
interquartile interval.
Significant CHD: Major stenosis over 75% in one of the major coronary artery.
Figure 1 Comparative survival of mitral plasty versus mitral
valve replacement.
Table 2 Crude effect of mitral plasty (MPL) versus mitral
valve replacement (MVR) on total mortality and re
operation and incidence of stroke and cerebral bleeding
at a mean follow up of 5.2 years
Total mortality and re operation
Variables MPL MVR Rate ratio with 95% CL P-value
Mortality 29 39 0.48(0.28-0.80) 0.001
Patients Years 1125 734
Re operation 14 17 0.61(0.28-1.31) 0.1775
Patients Years 1149 854
Morbidity stroke and cerebral bleeding
Stroke 8 10 0.52 (0.18-1.35) 0.1315
Cerebral bleeding 3 3 0.65 (0.08-4.90) 0.6171
Patients years 1125 734
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MVR. p = 0.1518 (Figure 2). A crude effect estimate
using the patient time model showed that the associ-
ation between procedure MPL/MVR and re operation
was quantified by RR = 0.58 (0.26-1.26) p = 0.1353 which
indicates no difference between the two the procedure
regarding the incidence of re operations Table 2.
A stratification analysis using the Mantel-Hanszel
methods on the person time model showed that presence
of significant CHD was the only variable with confounding
effect around 3.3% and the presence of atrial fibrillation
(AF) was an effect modifier.Adjusted effect of procedure on incidence of re operation
The adjusted effect of MPL/MVR procedure on re oper-
ation was done using the Cox’s model and controlling for
the confounding effect of presence of significant CHD and
the interaction between procedure and presence of AF.
Our results are shown in Table 3.
The interaction term continued to be statistically signifi-
cant (p = 0.028), because of interaction our results can be
summarized as follow. For non-AF patients performing
MPL will give us an RR = 0.32 95% CL (0.13-0.81) p =
0.017, indicating 68% less re-operation incidence for MPL
as compared with MVR. For patients with AF, there was no
difference in the incidence of re operation between repair
and replacement. In our study the prevalence of AF was
around 31% in accordance with the literature [1] and
our AF patients were older 68 years (62–73) for AF (+)
versus 60 years (50–68) for AF (−) p = 0001, they had a
larger left atrium diameter 53 mm (47–58) for AF (+)
versus 47 mm (40–53) for AF (−) p = 0.00001 and a
lower ejection fraction 56% (50–66) for AF (+) versus
Table 3 Adjusted effect of plasty procedure versus
replacement controlling for confounders and level of
interaction (effect modification)
Using the Cox’s regression model
Total mortality
Variables Level RR with 95% CL P-value
MPL/MVR Yes/No 0.43(0.28-0.74) 0.002
3 vessels CHD Yes/No 2.74(1.59-4.59) 0.0001
Reopration
MPL/MVR Yes/No 0.32(0.13-0.81) 0.017
AF Yes/No 0.47(0.15-1.47) 0.198
AF*(MPL/MVR) Interaction 5.6(1.21-26.6) 0.028
Presence significant CHD Yes/no 0.47(0.19-1.14) 0.091
Using the Cox’s model stratified by propensity score quintiles
Total mortality
Variables Level RR with 95% CL P-value
MPL/MVR Yes/no 0.54(0.32-0.90) 0.02
3 V CHD Yes/no 2.58(1.50-4.43) 0.001
Reoperation
MPL/MVR Yes/no 0.75(0.32-1.72) 0.502
Sig. CHD Yes/no 0.46(017–1.21) 0.1190
Interaction between MPL/MVR and AF:
Absence of AF: RR = 0.32 95% (0.13-0.81) p = 0.017.
Presence of AF: RR = 1.82 95% (0.52-6.4) p = 0.344.
As presence of AF is part of the propensity score. Interaction between MREP
and AF could not be performed.
Sig. CHD: Presence of significant coronary artery stenosis > 50% in one of the
major coronary artery.
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interquartile interval are presented).
Another approach was done by running a stratified
Cox’s model based on quintiles of PS and controlling
for the confounding effect of the variable presence of
significance CHD. This analysis gave an RR = 0.75 with
95% CL (0.32-1.72) p = 0.502 indicating no difference
in re operation incidence for MPL as compared toFigure 2 Comparative survival free of re operation between
mitral plasty and mitral replacement.MVR, at a mean follow up time of 5.3 years postopera-
tively. Investigating the interaction between presence
of AF and the procedure considered was impossible to
perform as presence of AF was one of the component var-
iables of the propensity score.Residual mitral regurgitation rate estimated by
echocardiography during follow up
The efficacy and durability of repair was estimated by
echocardiography on discharge and by a serial of echo-
cardiographic examinations performed at 3,12,36,60 and
120 months of follow up. This permitted us to estimate
the rate of new recurrent mitral regurgitation in events
per 100 patients years. The results are shown in Table 4,
the failure to repair is defined by recurrence of moderate
to severe mitral regurgitation or reoperation for mitral
regurgitation during a mean follow up postoperatively.
We had for grade 1 a rate of 3.9 per 100 patient years
for grade 2 1.86 per 100 patients years and for grade 3
the recurrence rate was 0.44 per 100 patients years,
respectively. Our follow up for MVR group was only
80% completed unfortunately.Discussion
The main findings of this study are 1) that long term
survival in patients operated with MPL was significant
better than MVR, 2) no significant difference between
the two groups was seen in thrombo-embolic episodes
or bleeding and 3) the need for reoperation was not
different between the MPL and MVR groups for patients
with atrial fibrillation. However, patients operated on sinus
rhythm with MPL not only lived longer compared to
patients receiving mitral prosthesis, but also had a
lower risk for reoperation.
Comparative studies of MPL/MVR are mostly ob-
servational retrospective cohort including our study.Table 4 Echocardiography control
Discharge echocardiography for the total cohort
Presence of MR MPL MVR Total
No MR 165 136 298
Grade 1 MR 37 4 41
Grade 2 MR 12 1 13
Grade 3 MR 0 0 0
Total late echocardiography at follow up






No MR 144 108 252
Grade 1 MR 44 (3.91) 2 (0.27) 46(2.47)
Grade 2 MR 21 (1.86) 4 (0.54) 25(1.34)
Grade 3 MR 5 (0.44) 0 (0) 5 (0.27)
Follow-up pat.years 1125 734 1859
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clinical trial comparing the 2 surgical procedures.
There is a variability as far inclusion of patients in those
study as the factors determining the timing of surgery. We
know that patients with left ventricular EF > 60% and left
ventricular systolic diameter < 45 mm are under medical
conservative treatment with ACE inhibitors and sometimes
with beta blockers. In a symptomatic patient with EF < 60%
and left ventricular end systolic diameter > 45 mm, MPL is
indicated when MPL is expected to be durable. In the
symptomatic patient with EF > 30% and left ventricular
end systolic diameter < 55 mm the MR patients are
candidates for MPL/MVR. (www.escardio.org/guidelines).
(The new 2012 ESC/EACTS Guidelines on the management
of valvular heart disease).
On the other hand there is also variability as far ex-
pertise of MPL in the major centres. Despite a consensus
in guidelines [19] encouraging MPL, it is interesting to
know that a significant number of patients with degen-
erative mitral valve disease still undergo planned mitral
valve replacement all over the world. Many patients are
operated with MVR despite repairable mitral valve path-
ology because surgeons who do not have the expertise to
complete a successful surgical repair given the aetiology
of degenerative disease could operate them.
Endpoint survival
Our results showing a better survival in patients operated
with MPL compared to MVR are in accordance with
previous studies of cohorts with mixed aetiologies.
The major end point of those cohorts was survival
(early and long term mortality) and survival free of
re-operation and thromboembolism. The distributions
of aetiology were: four degenerative myxomatous aetiology
cohorts [20-23], four ischemic aetiology cohorts [24-27],
while ten cohorts had mixed aetiologies [28-37]. Finally
two important studies were with rheumatic aetiology
[38,39]. In a meta analysis [1], the overall results of 21
studies as far survival pinpointed, a significant Hazard
ratio =0.63 95% CL (0.36-0.71) indicating a 37% reduced
risk of mortality for repair as compared to replacement
whatsoever aetiology. However, by stratifying on aetiology,
the beneficial effect on survival for repair compared to
replacement was evident for degenerative/myxomatous,
mixed and, rheumatic aetiologies. In patients with ischemic
aetiologies, the results are not conclusive. Because of
power limitation a subgroup analysis with stratification
on aetiology in our study could not be performed.
Unfortunately when interpreting studies on long term
survival it should be understood that available data refer
to the outcomes of MPL and cardiac surgery as prac-
ticed 10 to 20 years previously. Cardiac surgery has since
improved in several ways: for example, the widespread
adoption of blood cardioplegia has likely reduced theventricular damage during surgery, which in turn will
impact long-term survival.
Therefore no way of knowing the long-term survival
outcomes of mitral valve surgery as currently practised.
Based on what is published, it appears that if surgery is
undertaken before onset of symptoms and where left
ventricular function is preserved, the life expectancy
should be similar to that of the general population
[40-42]. When significant symptoms of heart failure have
developed NYHA-III or NYHA IV before mitral valve
surgery is undertaken, the long-term survival is reduced,
regardless of the left ventricular function [42].
Endpoint survival free from re-operation, atrial fibrillation
an effect modifier
In the literature we have found only 6 cohort studies
permitting to estimate re operation hazard ratio for
MPL compared to MVR [7,22,31,35,37,39]. The total
summary hazard ratio of these studies HR =0.88 95% CL
(0.48-1.62) suggests no difference in survival free from
re operation between the procedures repair/replacement,
and is in accordance with our study. The major reasons
for re operations were technical failure and valve related
causes such as infection, progression of disease and
thrombosis. Unfortunately none of those studies has
investigated and pinpointed the presence of AF as an
effect modifier for the association between procedure
and re-operation. The prevalence of AF at baseline was
around 31% and it is well known that in the early phase
of degenerative mitral disease treated conservatively the
most frequent echocardiographic findings is the enlarge-
ment of the left atrium in patients on sinus rhythm.
However paroxysmal or permanent AF ultimately affects
50% of patients within 10 years and after onset of AF an
increased cardiac mortality and morbidity is observed.
On the other hand patients who are surgically treated
with preoperative AF had a worse postoperative out-
come than those in Sinus Rhythm [41]. Grigioni F et al.
[42] found that risk of AF increases with advancing age
and larger LA dimension, in our study patients with AF
at baseline were older had larger LA diameter and lower
ejection fraction than patients in sinus rhythm. In con-
cordance with Grigioni F et al. our results suggest that
the clinical management of mitral disease should take
into account the high incidence and excess risk of AF
and more attention needs to be done in controlling its
predictors. On the other hand both outcomes total
mortality and re operation are not sensitive markers for
evaluation of the efficacy of repair as compared to
replacement. In fact failure of repair is mostly defined by
recurrence of moderate or severe mitral regurgitation or
re operation for mitral regurgitation. Failure rates of repair
are determined principally by the original dysfunction and
by the repair technique.
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Carpentier technique, Baumberger et al. [43] Showed on
patients with degenerative aetiology 97% of patients with
posterior leaflet, 86% with anterior leaflet and 83.5% with bi
leaflet prolapsed were free from re operation at 20 years.
They also found that only 74% were free from cardiac
related events at 20 years. This difference between freedom
from re operation and freedom from cardiac events,
however pinpoint the limitations of outcome survival
free from re operation as a good end point measure of
the efficacy of MPL. Because of that we have enough
evidence nowadays that survival and re operation rates
are weak surrogates for adequacy of repair during the
follow up time after mitral valve surgery.
Importance of echocardiography follow up over time
Long term echocardiography follow up data are scarce
in the medical literature, probably due to a high drop
out rate of the patients as shown in long-term follow up
study of MPL. David TE et al. [44] presented incomplete
50% drop out follow up date on echocardiographic
follow up. Our study also suffered of 20% drop out
mainly in the MVR group. The lack of systematic
echocardiographic follow-up is the major limiting factor
in determining the true durability of all MPL techniques
[45]. Most cohort studies in the literatures [1] have focused
on survival and re operation rate, which may not necessar-
ily reflect the durability of repair. The most complete serial
echocardiographic follow up data for MPL is from Flameng
et al. [46]. They performed echocardiografic examinations
in a serial follow up done at 6 months intervals like our
protocol. After 7 years the, freedom from moderate or
severe MR was 71%. New recurrent mitral regurgitation
appeared at a rate of 3.7% per year. The recurrence rate
per year was 8.3% for MR grade > I, and 3.4% for MR
grade > II. These results are in accordance with ours
showing a recurrence rate of 2.3% per year for MR
grade ≥ II and pinpointing a MR recurrence rate of 2.30 per
% per year for MR Grade > =II. Furthermore, our results
are concordant with Flameng et al. and underline that
durability of many MPLs is limited. The linear recurrence
rate implies that recurrent mitral regurgitation probably re-
flects the progression of mitral valve disease, while technical
failure is the major cause of early regurgitation [47].
Conclusion
As a conclusion our results suggest a beneficial effect of
MV-repair compared to MV-replacement on total mor-
tality and re operation for patients on sinus rhythm. For
patients with AF it is beneficial only for mortality. We
advocate more attention in controlling risk factors of AF
in the clinical management of mitral disease. Being in a
non-randomised design our results need to be replicated
to be conclusive by a randomised clinical trial withstratification on different aetiologies and on the presence
of atrial fibrillation. The major end points of this trial
will be the durability and adequacy of repair and the
impact of repair on left ventricular systolic functions
over time using a serial echocardiographic follow up.
Consent
Written informed consent was obtained from the patient
for publication of this report.
Abbreviations
MPL: Mitral plasty; MVR: Mitral valve replacement; MR: Mitral regurgitation;
MS: Mitral stenose; AF: Atrial fibrillation; AS: Aortic stenosis; TR: Tricuspidal
regurgitation; AR: Aortic regurgitation; PS: Propensity score; SE: Standard
error.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors: 1) have made substantial contributions to conception and
design, or acquisition of data, or analysis and interpretation of data; 2) have
been involved in drafting the manuscript or revising it critically for important
intellectual content; and 3) have given final approval of the version to be
published.
Author details
1Dept of Cardiothoracic Surgery, Oslo University Hospital, Ullevaal, Norway.
2Centre of Clinical Research: Unit of Epidemiology and Biostatistics, Oslo
University Hospital, Ullevaal, Norway. 3Centre for Clinical Heart Research, Oslo
University Hospital, Ullevaal, Norway. 4Dept of Cardiology, Oslo University
Hospital, Ullevaal, Norway.
Received: 16 January 2013 Accepted: 27 May 2013
Published: 1 June 2013
References
1. Shuhaiber J, Anderson RJ: Meta-analysis of clinical outcomes following
surgical mitral valve repair or replacement. Eur J Cardiothorac Surg 2007,
31(2):267–75.
2. Rao C, Murphy MO, Saso S, Pandis D, Grapsa J, Nihoyannopoulos P, Reeves
BC, Athanasiou T: Mitral valve repair or replacement for ischaemic mitral
regurgitation: a systematic review. Heart Lung Circ 2011, 20(9):555–65.
3. Murphy MO, Rao C, Punjabi PP, Athanasiou T: In patients undergoing mitral
surgery for ischaemic mitral regurgitation is it preferable to repair or
replace the mitral valve? Interact Cardiovasc Thorac Surg 2011, 12(2):218–227.
4. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA,
Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ,
Waggoner A, Weissman NJ, American Society of Echocardiography:
Recommendations for evaluation of the severity of native valvular
regurgitation with two-dimensional and Doppler echocardiography.
J Am Soc Echocardiogr 2003, 16(7):777–802.
5. Abdelnoor M, Fjeld NB, Vaage K, Svennevig JL, Klingen G, Wickstrom E,
Sivertssen E, Semb G: Risk factors for morbidity and mortality in mitral
valve replacement. Eur J Cardiothorac Surg 1990, 4(8):425–30.
6. Cohn LH, Kowalker W, Bhatia S, DiSesa VJ, St John-Sutton M, Shemin RJ,
Collins JJ Jr: Comparative morbidity of mitral valve repair versus
replacement for mitral regurgitation with and without coronary artery
disease. Ann Thorac Surg 1988, 45(3):284–90.
7. Moss RR, Humphries KH, Gao M, Thompson CR, Abel JG, Fradet G, Munt BI:
Outcome of mitral valve repair or replacement: a comparison by
propensity score analysis. Circulation 2003, 108(Suppl 1):II90–7.
8. Gillinov AM, Blackstone EH, Nowicki ER, Slisatkorn W, Al-Dossari G, Johnston
DR, George KM, Houghtaling PL, Griffin B, Sabik JF 3rd, Svensson LG: Valve
repair versus valve replacement for degenerative mitral valve disease.
J Thorac Cardiovasc Surg 2008, 135(4):885–893. 893.e1-2.
9. Kleinbaum DG, Kupper L, Morgenstern H: Epidemiologic research. Principles and
quantitative methods. New york: Van Nostrand Reinhold Compagny; 1982.
Vengen et al. Journal of Cardiothoracic Surgery 2013, 8:142 Page 8 of 8
http://www.cardiothoracicsurgery.org/content/8/1/14210. Kleinbaum DG, Klein M: Survival analysis: a self learning Text. 2nd edition.
New York, NY: Springer Science + Business Media; 2005.
11. D’Agostino RB Jr: Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group.
Stat Med 1998, 17(19):2265–81.
12. Rosenbaum R, Rubin DB: The central role of propensity score in
observational studies of Causal effect. Biometrica 1983, 70:41–55.
13. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR: A simulation
study of the number of events per variable in logistic regression
analysis. J Clin Epidemiol 1996, 49(12):1373–9.
14. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S: A review
of the application of propensity score methods yielded increasing use,
advantages in specific settings, but not substantially different estimates
compared with conventional multivariable methods. J Clin Epidemiol
2006, 59(5):437–447.
15. Kleinbaum DG, Klein M: Logistic Regression: a self learning Text. 3rd edition.
New York, NY: Springer-Verlag; 2010.
16. Austin PC: Propensity-score matching in the cardiovascular surgery
literature from 2004 to 2006: a systematic review and suggestions for
improvement. J Thorac Cardiovasc Surg 2007, 134(5):1128–35.
17. Blackstone EH: Comparing apples and oranges. J Thorac Cardiovasc Surg
2002, 123(1):8–15.
18. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V: Principles for
modeling propensity scores in medical research: a systematic literature
review. Pharmacoepidemiol Drug Saf 2004, 13(12):841–53.
19. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G,
Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L,
Wenink A: Task Force on the Management of Valvular Hearth Disease of
the European Society of Cardiology; ESC Committee for Practice
Guidelines. Guidelines on the management of valvular heart disease:
The Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology. Eur Heart J 2007, 28(2):230–68.
20. Gillinov AM, Faber C, Houghtaling PL, Blackstone EH, Lam BK, Diaz R, Lytle
BW, Sabik JF 3rd, Cosgrove DM 3rd: Repair versus replacement for
degenerative mitral valve disease with coexisting ischemic heart disease.
J Thorac Cardiovasc Surg 2003, 125(6):1350–62.
21. Lee EM, Shapiro LM, Wells FC: Superiority of mitral valve repair in surgery
for degenerative mitral regurgitation. Eur Heart J 1997, 18(4):655–63.
22. Mohty D, Orszulak TA, Schaff HV, Avierinos JF, Tajik JA, Enriquez-Sarano M:
Very long-term survival and durability of mitral valve repair for mitral
valve prolapse. Circulation 2001, 104(12 Suppl 1):I1–I7.
23. Yacoub M, Halim M, Radley-Smith R, McKay R, Nijveld A, Towers M: Surgical
treatment of mitral regurgitation caused by floppy valves: repair versus
replacement. Circulation 1981, 64(2 Pt 2):II210–6.
24. Calafiore AM, Di Mauro M, Gallina S, Di Giammarco G, Iacò AL, Teodori G,
Tavarozzi I: Mitral valve surgery for chronic ischemic mitral regurgitation.
Ann Thorac Surg 2004, 77(6):1989–97.
25. Cohn LH, Rizzo RJ, Adams DH, Couper GS, Sullivan TE, Collins JJ Jr, Aranki
SF: The effect of pathophysiology on the surgical treatment of ischemic
mitral regurgitation: operative and late risks of repair versus
replacement. Eur J Cardiothorac Surg 1995, 9(10):568–74.
26. Grossi EA, Goldberg JD, LaPietra A, Ye X, Zakow P, Sussman M, Delianides J,
Culliford AT, Esposito RA, Ribakove GH, Galloway AC, Colvin SB: Ischemic
mitral valve reconstruction and replacement:comparison of long-term
survival and complications. J Thorac Surg 2001, 122(6):1107–24.
27. Mantovani V, Mariscalco G, Leva C, Blanzola C, Cattaneo P, Sala A: Long-term
results of the surgical treatment of chronic ischemic mitral regurgitation:
comparison of repair and prosthetic replacement. J Heart Valve Dis 2004,
13(3):421–8. discussion 428–9.
28. Abedo OA, Ross JK: Surgical treatment of ruptured mitral valve cordea.
A comparison between valve replacement and repair. Thorac Cardiovasc
Surgeon 1994, 32:139–142.
29. Akins CW, Hilgenberg AD, Buckley MJ, Vlahakes GJ, Torchiana DF, Daggett
WM, Austen WG: Mitral valve reconstruction versus replacement for
degenerative or ischemic mitral regurgitation. Ann Thorac Surg 1994,
58(3):668–75. discussion 675–6.
30. Craver JM, Cohen C, Weintraub WS: Case-matched comparison of mitral
valve replacement and repair. Ann Thorac Surg 1990, 49(6):964–9.
31. Enriquez-Sarano M, Schaff HV, Orszulak TA, Tajik AJ, Bailey KR, Frye RL:
Valve repair improves the outcome of surgery for mitral regurgitation.
A multivariate analysis. Circulation 1995, 91(4):1022–8.32. Galloway AC, Colvin SB, Baumann FG, Grossi EA, Ribakove GH, Harty S,
Spencer FC: A comparison of mitral valve reconstruction with mitral
valve replacement: intermediate-term results. Ann Thorac Surg 1989,
47(5):655–62.
33. Hausman H, Siniaski H, Hertzer R: Mitral valve reconstruction and
replacement for ischemic Mitral insufficiency. Seven years follow up.
J Heart Valve Dis 1999, 47:655–62.
34. Kawachi Y, Oe M, Asou T, Tominaga R, Tokunaga K: Comparative study
between valve repair and replacement for mitral pure regurgitation–early
and late postoperative results. Jpn Circ J 1991, 55(5):443–52.
35. Perier P, Deloche A, Chauvaud S, Fabiani JN, Rossant P, Bessou JP, Relland J,
Bourezak H, Gomez F, Blondeau P, et al: Comparative evaluation of mitral
valve repair and replacement with Starr, Björk, and porcine valve
prostheses. Circulation 1984, 70(3 Pt 2):I187–92.
36. Sand ME, Naftel DC, Blackstone EH, Kirklin JW, Karp RB: A comparison of
repair and replacement for mitral valve incompetence. J Thorac
Cardiovasc Surg 1987, 94(2):208–219.
37. Thourani VH, Weintraub WS, Guyton RA, Jones EL, Williams WH, Elkabbani S,
Craver JM: Outcomes and long-term survival for patients undergoing
mitral valve repair versus replacement: effect of age and concomitant
coronary artery bypass grafting. Circulation 2003, 108(3):298–304.
38. Antunes MJ: Mitral valvuloplasty, a better alternative. J Cardiovasc Surg
2000, 119:53–61.
39. Yau TM, El-Ghoneimi YA, Armstrong S, Ivanov J, David TE: Mitral valve
repair and replacement for rheumatic disease. J Thorac Cardiovasc Surg
2000, 119(1):53–60.
40. Enriquez-Sarano M, Tribouilloy C: Quantitation of mitral regurgitation:
rationale, approach, and interpretation in clinical practice. Heart 2002,
88(Suppl 4):iv1–3.
41. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik
AJ, Frye RL: Impact of preoperative symptoms on survival after surgical
correction of organic mitral regurgitation: rationale for optimizing
surgical indications. Circulation 1999, 99(3):400–5.
42. Grigioni F, Avierinos JF, Ling LH, Scott CG, Bailey KR, Tajik AJ, Frye RL,
Enriquez-Sarano M: Atrial fibrillation complicating the course of
degenerative mitral regurgitation: determinants and long-term outcome.
J Am Coll Cardiol 2002, 40(1):84–92.
43. Braunberger E, Deloche A, Berrebi A, Abdallah F, Celestin JA, Meimoun P,
Chatellier G, Chauvaud S, Fabiani JN, Carpentier A: Very long-term results
(more than 20 years) of valve repair With Carpentier techniques in
non-reheumatic mitral valve insufficiency. Circulation 2001,
104(I2-Suppl 1):I8–11.
44. David TE, Ivanov J, Armstrong S, Christie D, Rakowski H: A comparison of
outcomes of mitral valve repair for degenerative disease with posterior,
anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg 2005,
130(5):1242–1249.
45. Adams DH, Anyanwu A: Pitfalls and limitations in measuring and
interpreting the outcomes of mitral valve repair. J Thorac Cardiovasc Surg
2006, 131(3):523–9.
46. Flameng W, Herijgers P, Bogaerts K: Recurrence of mitral valve
regurgitation after mitral valve repair in degenerative valve disease.
Circulation 2003, 107(12):1609–13.
47. Shekar PS, Couper GS, Cohn LH: Mitral valve re-repair. J Heart Valve Dis
2005, 14(5):583–7.
doi:10.1186/1749-8090-8-142
Cite this article as: Vengen et al.: Outcome of mitral valve plasty or
replacement: atrial fibrillation an effect modifier. Journal of Cardiothoracic
Surgery 2013 8:142.
